Do analysts rate ALVR or YARW?

Yarrow Bioscience has a consensus price target of $58.00, indicating a potential upside of 101.04%. Given Yarrow Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Yarrow Bioscience is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Yarrow Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts prefer ALVR or GANX?

Gain Therapeutics has a consensus target price of $7.50, indicating a potential upside of 312.09%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Gain Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is ALVR or GANX more profitable?

AlloVir's return on equity of -71.03% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Gain Therapeutics N/A -161.59% -118.36%

Do analysts recommend ALVR or TELO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, ALVR or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.91 N/A

Is ALVR or TELO more profitable?

AlloVir's return on equity of -71.03% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Telomir Pharmaceuticals N/A -102.70% -90.75%

Do analysts rate ANVS or ALVR?

Annovis Bio presently has a consensus price target of $12.00, indicating a potential upside of 775.91%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, ANVS or ALVR?

Annovis Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.79 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is ANVS or ALVR more profitable?

AlloVir's return on equity of -71.03% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -685.98% -258.77% AlloVir N/A -71.03% -61.27%

Do analysts prefer ALVR or PLRX?

Pliant Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 165.49%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pliant Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75

Is ALVR or PLRX more profitable?

Pliant Therapeutics' return on equity of -52.17% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Pliant Therapeutics N/A -52.17% -40.46%

AlloVir (ALVR) Competitors

$3.90 -0.02 (-0.51%)

As of 09/2/2026

Compare

ALVR vs. YARW, GANX, TELO, ANVS, and PLRX

Should you buy AlloVir stock or one of its competitors? AlloVir's main competitors and comparable companies include Yarrow Bioscience (YARW), Gain Therapeutics (GANX), Telomir Pharmaceuticals (TELO), Annovis Bio (ANVS), and Pliant Therapeutics (PLRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AlloVir compare to Yarrow Bioscience?

AlloVir (NASDAQ:ALVR) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Yarrow Bioscience has higher revenue and earnings than AlloVir. Yarrow Bioscience is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Yarrow Bioscience	$570K	135.14	-$26.48M	-$14.64	N/A

66.1% of AlloVir shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Yarrow Bioscience had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Yarrow Bioscience and 0 mentions for AlloVir. Yarrow Bioscience's average media sentiment score of 0.84 beat AlloVir's score of 0.00 indicating that Yarrow Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Yarrow Bioscience	Positive

AlloVir has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. AlloVir's return on equity of -71.03% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Yarrow Bioscience has a consensus price target of $58.00, indicating a potential upside of 101.04%. Given Yarrow Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Yarrow Bioscience is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market.

Summary

Yarrow Bioscience beats AlloVir on 10 of the 15 factors compared between the two stocks.

How does AlloVir compare to Gain Therapeutics?

AlloVir (NASDAQ:ALVR) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

In the previous week, Gain Therapeutics had 10 more articles in the media than AlloVir. MarketBeat recorded 10 mentions for Gain Therapeutics and 0 mentions for AlloVir. Gain Therapeutics' average media sentiment score of 0.27 beat AlloVir's score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Gain Therapeutics	Neutral

AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

Gain Therapeutics has higher revenue and earnings than AlloVir. Gain Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Gain Therapeutics	$50K	1,588.50	-$20.16M	-$0.50	N/A

Gain Therapeutics has a consensus target price of $7.50, indicating a potential upside of 312.09%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

AlloVir's return on equity of -71.03% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Gain Therapeutics	N/A	-161.59%	-118.36%

66.1% of AlloVir shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Gain Therapeutics beats AlloVir on 8 of the 14 factors compared between the two stocks.

How does AlloVir compare to Telomir Pharmaceuticals?

AlloVir (NASDAQ:ALVR) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

AlloVir's return on equity of -71.03% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

66.1% of AlloVir shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, AlloVir's average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
AlloVir	Neutral
Telomir Pharmaceuticals	Neutral

Summary

AlloVir beats Telomir Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does AlloVir compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Annovis Bio has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

In the previous week, Annovis Bio had 4 more articles in the media than AlloVir. MarketBeat recorded 4 mentions for Annovis Bio and 0 mentions for AlloVir. Annovis Bio's average media sentiment score of 0.41 beat AlloVir's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Annovis Bio	Neutral
AlloVir	Neutral

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Annovis Bio presently has a consensus price target of $12.00, indicating a potential upside of 775.91%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Annovis Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

AlloVir's return on equity of -71.03% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
AlloVir	N/A	-71.03%	-61.27%

Summary

Annovis Bio beats AlloVir on 8 of the 13 factors compared between the two stocks.

How does AlloVir compare to Pliant Therapeutics?

AlloVir (NASDAQ:ALVR) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Pliant Therapeutics' return on equity of -52.17% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Pliant Therapeutics	N/A	-52.17%	-40.46%

66.1% of AlloVir shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Pliant Therapeutics has higher revenue and earnings than AlloVir. Pliant Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Pliant Therapeutics	$1.58M	44.28	-$149.34M	-$1.49	N/A

In the previous week, Pliant Therapeutics had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Pliant Therapeutics and 0 mentions for AlloVir. Pliant Therapeutics' average media sentiment score of 0.59 beat AlloVir's score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Pliant Therapeutics	Positive

Pliant Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 165.49%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Summary

Pliant Therapeutics beats AlloVir on 12 of the 14 factors compared between the two stocks.

Get AlloVir News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVR vs. The Competition

Export

Metric	AlloVir	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$19.67M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.19	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	0.13	16.29	12.89	6.14
Net Income	-$190.42M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-4.88%	0.34%	0.60%	-0.27%
1 Month Performance	-3.70%	8.52%	5.73%	0.68%
1 Year Performance	-14.66%	52.66%	25.35%	14.84%

AlloVir Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVR AlloVir	N/A	$3.90 -0.5%	N/A	-2.5%	$19.67M	N/A	N/A	110
YARW Yarrow Bioscience	2.2927 of 5 stars	$29.49 -4.8%	$58.00 +96.7%	N/A	$78.75M	$570K	N/A	30	News Coverage Short Interest Increase Gap Down
GANX Gain Therapeutics	2.4248 of 5 stars	$1.78 +0.3%	$7.50 +322.5%	-5.2%	$77.47M	N/A	N/A	20	Positive News Analyst Revision
TELO Telomir Pharmaceuticals	0.4096 of 5 stars	$1.12 +1.4%	N/A	-1.7%	$76.68M	N/A	N/A	1
ANVS Annovis Bio	2.8927 of 5 stars	$1.72 +1.5%	$11.33 +560.8%	-40.1%	$73.07M	N/A	N/A	3	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVR) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AlloVir (ALVR) Competitors

ALVR vs. YARW, GANX, TELO, ANVS, and PLRX

How does AlloVir compare to Yarrow Bioscience?

Summary

How does AlloVir compare to Gain Therapeutics?

Summary

How does AlloVir compare to Telomir Pharmaceuticals?

Summary

How does AlloVir compare to Annovis Bio?

Summary

How does AlloVir compare to Pliant Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AlloVir (ALVR) Competitors

ALVR vs. YARW, GANX, TELO, ANVS, and PLRX

How does AlloVir compare to Yarrow Bioscience?

Which has better earnings and valuation, ALVR or YARW?

Do institutionals & insiders have more ownership in ALVR or YARW?

Does the media refer more to ALVR or YARW?

Is ALVR or YARW more profitable?

Do analysts rate ALVR or YARW?

Which has more volatility and risk, ALVR or YARW?

Summary

How does AlloVir compare to Gain Therapeutics?

Does the media refer more to ALVR or GANX?

Which has more risk and volatility, ALVR or GANX?

Which has stronger earnings & valuation, ALVR or GANX?

Do analysts prefer ALVR or GANX?

Is ALVR or GANX more profitable?

Do insiders and institutionals believe in ALVR or GANX?

Summary

How does AlloVir compare to Telomir Pharmaceuticals?

Which has more volatility and risk, ALVR or TELO?

Which has higher earnings & valuation, ALVR or TELO?

Is ALVR or TELO more profitable?

Do analysts recommend ALVR or TELO?

Do institutionals and insiders believe in ALVR or TELO?

Does the media refer more to ALVR or TELO?

Summary

How does AlloVir compare to Annovis Bio?

Which has more risk and volatility, ANVS or ALVR?

Does the media prefer ANVS or ALVR?

Do insiders and institutionals have more ownership in ANVS or ALVR?

Do analysts rate ANVS or ALVR?

Which has stronger earnings & valuation, ANVS or ALVR?

Is ANVS or ALVR more profitable?

Summary

How does AlloVir compare to Pliant Therapeutics?

Is ALVR or PLRX more profitable?

Do institutionals and insiders believe in ALVR or PLRX?

Which has higher earnings and valuation, ALVR or PLRX?

Does the media favor ALVR or PLRX?

Do analysts prefer ALVR or PLRX?

Which has more risk and volatility, ALVR or PLRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools